ATTR-amyloidosis - a systemic disease involving the kidneys

ATTR amyloidosis (transthyretin amyloidosis) is a progressive, fatal disease characterized by the accumulation of transthyretin amyloid mainly in the peripheral nervous system (somatic and autonomic) and heart, as well as in the kidneys, gastrointestinal tract, eyeballs, and ligaments, which impairs the normal function of organs and systems. The hereditary form of ATTR amyloidosis, or ATTRv amyloidosis, is found all over the world and is characterized by broad genetic and phenotypic heterogeneity, resulting in late diagnosis. The kidneys are a potential target organ in ATTRv amyloidosis. Clinically, nephropathy is manifested by albuminuria, proteinuria, nephrotic syndrome, or decreased renal function. A nephrologist may be involved in the diagnosis of amyloid nephropathy/ATTRv amyloidosis in a patient with symptoms of renal damage in an endemic region or with a family history of ATTRv amyloidosis, or, more difficult, in the diagnosis of a sporadic case of ATTRv amyloidosis when symptoms of nephropathy were detected in a patient in a non-endemic region without a known family history of amyloidosis. The diagnosis of amyloidosis, especially is sporadic cases, requires the nephrologist to know the specific symptoms, the so-called "red flags" of ATTR amyloidosis that allow suspecting amyloidosis, and methods to confirm the diagnosis. Kidney biopsy in the presence of nephropathy is the gold standard in the diagnosis of amyloidosis. Congo-red staining of biopsy specimens with subsequent visualization of the apple-green birefringence of congophilic masses with polarized light is crucial for histological confirmation of the diagnosis. Immunohistochemistry is used for amyloid typing. The less available method for typing is mass spectrometry of affected tissue. Detection of "red flags" of amyloidosis in a patient with nephropathy makes it possible to diagnose ATTR amyloidosis in some cases without a biopsy, by TTR gene sequencing or myocardial scintigraphy with 99mTc-pyrophosphate. After amyloidosis is diagnosed, it is necessary to conduct a detailed examination for assessing the damage to potential target organs, which requires an interdisciplinary approach. Early diagnosis and disease-modifying therapies can slow the progression of neuropathy and cardiomyopathy, and presumably nephropathy.

ATTR-амилоидоз, ATTRv-амилоидоз, амилоидная нефропатия, диагностика, транстиретиновый амилоидоз, наследственный ATTR-амилоидоз, ATTR amyloidosis, ATTRv amyloidosis, transthyretin amyloid nephropathy, diagnosis, transthyretin amyloidosis, hereditary ATTR amyloidosis

1. Лысенко (Козловская) Л.В., Рамеев В.В., Моисеев С.В. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клиническая фармакология и терапия. 2020; 29(1): 13-24. doi: 10.32756/ 0869-5490-2020-1-13-24.

2. Бакулина Н.В., Некрасова А.С., Гудкова А.Я. и соавт. Системный амилоидоз: клинические проявления и диагностика. Эффективная фармакотерапия. 2020; 16 (24): 68-76. doi: 10.33978/2307-3586-2020-16-24-68-76.

3. Dember L. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006; 17(12): 3458-71. doi: 10.1681/ASN.2006050460.

4. Benson M., Buxbaum J., Eisenberg D. et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020; 27(4): 217-222. doi: 10.1080/13506129.2020.1835263.

5. Zhen D., Swiecicki P., Zeldenrust S. et al. Frequencies and geographic distributions of genetic mutations in transthyretin and non- transthyretin-related familial amyloidosis. Clin Genet. 2015; 88(4): 396-400. doi: 10.1111/cge.12500.

6. Adams D., Koike H., Slama M., T. Coelho Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019; 15(7): 387-404. doi: 10.1038/s41582-019-0210-440.

7. Lachmann H., Booth D., Booth S. et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346(23):1786-1791. doi: 10.1056/NEJMoa013354.

8. Гудкова А.Я., Амелин А.В., Крутиков А.Н. и соавт. Val30Met-транстиретиновая амилоидная полиневропатия и кардиомиопатия (обзор литературы и клиническое наблюдение). Consilium Medicum. 2017; 19 (12): 109-116. doi: 10.26442/2075-1753_19.12.109-116.

9. Рамеев В.В., Мясников Р.П., Виноградов П.П. и соавт. Системный ATTR-амилоидоз, редкая форма поражения внутренних органов. Рациональная Фармакотерапия в Кардиологии. 2019; 15(3): 349-358. doi: 10.20996/1819-6446-2019-15-3-349-358.

10. Резник Е.В., Нгуен Т.Л., Степанова Е.А. и соавт. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020; 10(6): 430-457. doi: 10.20514/2226-6704-2020-10-6-430-457.

11. Adams D., Ando Y., Beirão J. et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021; 268(6): 2109-2122. doi: 10.1007/s00415-019-09688-0.

12. Аndo Y., Coelho T., Berk J. et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 20(8): 31. doi: 10.1186/1750-1172-8-31.

13. Gertz M., Adams D., Ando Y. et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020; 21(1): 198. doi: 10.1186/s12875-020-01252-4.

14. Maurer M., Bokhari S., Damy T. et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019; 12(9): e006075. doi: 10.1161/CIRCHEARTFAILURE.119.006075.

15. Koike H., Katsuno M. Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies. Neurol Ther. 2020; 9(2): 317-333. doi: 10.1007/s40120-020-00210-7.

16. Никитин С.С., Бардаков С.Н., Супонева Н.А. и соавт. Фенотипическая гетерогенность и особенности транстиретинового амилоидоза с полинейропатией. Нейромышечные болезни. 2021; 11(3): 12-36. doi: 10.17650/2222-8721-2021-11-3-12-36.

17. Schmidt H., Waddington-Cruz M., Botteman M. et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018; 57(5): 829-837. doi: 10.1002/mus.26034.

18. Gertz M., Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020; 324(1): 79-89. doi:10.1001/jama.2020.5493.

19. Obici L., Adams D. Acquired and inherited amyloidosis: knowledge driving patients’ care. J Peripher Nerv Syst. 2020; 25: 85-101. doi: 10.1111/jns.12381.

20. Rowczenio D., Noor I., Gillmore J. et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum. Mutat. 2014; Sep; 35(9): E2403-12. doi: 10.1002/humu.22619.

21. Conceição I., González-Duarte A., Obici L. et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016; 21(1): 5-9. doi: 10.1111/jns.12153.

22. Beirão J., Malheiro J., Lemos C. et al. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015; 22 (2): 117-122. doi:10.3109/13506129.2015.1015678.

23. Luigetti M. Romano A., Di Paolantonio A. et al. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care Ther. Clin. Risk Manag. 2020; 16: 109-123. doi: 10.2147/TCRM.S219979.

24. Maurer M., Hanna M., Grogan M. et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). Am Coll Cardiol. 2016; Jul 12; 68(2): 161-72. doi: 10.1016/j.jacc.2016.03.596.

25. Lobato L., Beirгo I., Silva M. et al. Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transpl. 2003; 18:v532-8. doi: 10.1093/ndt/18.3.532.

26. Rocha A., Lobato L. Liver transplantation in transthyretin amyloidosis: Characteristics and management related to kidney disease. Transplant Rev (Orlando). 2017; 31(2): 115-120. doi:10.1016/j.trre.2016.09.002.

27. Weber M.L., Ibrahim H.N., Lake J.R. Renal dysfunction in liver transplant recipients: evaluation of critical issues. Liver Transplantation. 2012; 18: 1290-301.

28. Lobato L., Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol. 2012; 7:1 337-46. doi: 10.2215/cjn.08720811.

29. Ikeda S., Hanyu N., Hongo M. et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain. 1987; 110 (2): 315-37. doi: 10.1093/brain/110.2.315.

30. Lobato L. Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M). J Nephrol. 2003; 16: 438-442.

31. Lobato L., Beirão I., Silva M.et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid. 2004; 11(1): 27-37. doi: 10.1080/13506120410001673884.

32. Ferraro P., D’Ambrosio V., Di Paolantonio A. et al. Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. Brain Sci. 2021; 11(8): 980. doi: 10.3390/brainsci11080980.

33. Moreira C.L., Rocha A., Santos J. et al. The ever-growing understanding of transthyretin amyloidosis nephropathy. Amyloid 2017; 24: 117-8. doi: 10.1080/13506129.2017.1293645.

34. Lobato L., Beirгo I., Guimarгes S.M. et al. Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits. Am J Kidney Dis. 1998; 31: 940-6. doi: 10.1053/ajkd.1998.v31.pm9631837.

35. Westermark P., Bergstrom J., Solomon A. et al. Transthyretin-derived senile systemic amyloidosis: Clinicopathologic and structural considerations. Amyloid. 2003; 10 (Suppl 1):48-54.

36. Yoshimura Y., Kuwabara T., Shiraishi N.et al. Transthyretin -related familial amyloidotic polyneuropathy found with abnormal urinanalysis at a general health checkup. Nephrology (Carlton). 2016; 21(4): 341-2. doi: 10.1111/nep.12610.

37. Xu J., Yang M., Pan X. et al. Transthyretin-related hereditary amyloidosis with recurrent vomiting and renal insufficiency as the initial presentation. Medicine (Baltimore). 2017; 96(10): e5737. doi: 10.1097/MD.0000000000005737.

38. Planté-Bordeneuve V., Said G. Lancet Neurol 2011; 10: 1086-97. doi: 10.1016/S1474-4422(11)70246-0.

39. Супонева Н.А., Ризванова А.С., Белова Н.В. Современные представления о лечении пациентов с транстиретиновой семейной амилоидной полиневропатией. Нервные болезни. 2019; 2: 18-24. doi: 10.24411/2226-0757-2019-12100.

40. Gertz M.A., Mauermann M.L., Grogan M., Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain Behav. 2019; 9(9): e01371. doi:10.1002/brb3.1371.

41. Adams D. European Network for TTR-FAP (ATTReuNET). First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016 Feb; 29 Suppl 1(Suppl 1): S14-26.

42. Coelho T., Inês M., Conceição I., Soares M et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018; 91(21): e1999-e2009. doi:10.1212/WNL.0000000000006543.

43. Инструкция по медицинскому применению лекарственного препарата Виндакель ЛП-004181.

44. Инструкция по медицинскому применению лекарственного препарата Виндамэкс ЛП-007319.

45. Rocha A., Silva A., Cardoso M. et al. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule. Amyloid. 2017; 24: 81-2. doi: 10.1080/13506129.2016.1277697.

46. Ferrer-Nadal A., Ripoll T., Uson M. et al. Significant reduction in proteinuria after treatment with tafamidis. Amyloid. 2019; 26(sup1): 67-68. doi: 10.1080/13506129.2019.1583186.